U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07203118) titled 'A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B' on Sept. 15.
Brief Summary: UsingTAF as the control, the nvestigators aim to further explore the efficacy and safety of different dosages of HTS in the treatment of patients with chronic hepatitis B; ultimately, the nvestigators determine the optimal recommended dosage of HTS to provide a basis for Phase III confirmatory clinical research.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Chronic Hepatitis B
Intervention:
DRUG: HTS 20mg
Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or...